Kevin Eberman received his Ph.D. in Materials Science at the Massachusetts Institute of Technology in 1998. Following a post-doc appointment at the Max Planck Institute for Solid-State Research, where he had a paper published in Nature, he commenced at 3M in the Li-ion battery (LIB) group developing anode and cathode materials for LIBs. Dr Eberman was the technical lead in launching a new class of the cathode materials called “NMC”. From 2006 to 2010 he worked at Medtronic as a Principal Scientist in the battery research group, contributing to Li-ion and primary battery research, development, and production.
In 2010 he re-joined 3M in a management role for the LIB research group. In addition to developing electrolyte, binder, current-collector, and high-voltage cathode materials, the 3M team developed the leading Si-alloy materials. Dr Eberman currently provides technical leadership for the development of improved batteries for 3M’s line of professional safety equipment, and advises on all things battery at 3M. He has 22 publications and 11 patents or patent applications.
Oliver Gross holds both a BS and a Master’s Degree in Materials Science from the University of Toronto. Oliver has 20 years’ experience in the advanced energy storage industry. He currently holds the position of Walter P. Chrysler Technical Fellow, for Energy Storage Systems, at Stellantis (formally Fiat Chrysler Automobiles), where he is responsible for the Battery systems technology roadmap and architecture for Stellanits. He is a member of the United States Advanced Battery Consortium Technical Advisory Committee, and chairs the committees on 12V Stop-Start and 48V Mild Hybrid batteries. He is also Chairman for the Society for Automotive Engineers’ Work Group on Capacitive Energy Storage Systems. He holds both a BS and a Master’s Degree in Materials Science, from the University of Toronto.
Prior to Chrysler Oliver was at Cobasys, where he was responsible for all Nickel Metal-Hydride cell and module development and the development of their lithium-ion battery portfolio. Before Cobasys, Oliver was at Valence Technology, where he was responsible for lithium-ion cell design and development, which included extended-term deployments to Northern Ireland, South Korea, and China. Before Valence, Oliver was at Ultralife, developing lithium primary and secondary cells for extreme environment applications. He currently holds over 10 patents, and more than 20 publications.
Paul Young is Professor of Virology and Head of School (School of Chemistry & Molecular Biosciences) at the University of Queensland, Brisbane, Australia. He completed his basic science degree in Australia before moving to the UK where he was awarded his PhD in 1986 from the London School of Hygiene & Tropical Medicine. He began his dengue research program at the LSHTM, initially in the area of vaccine development and supported by the WHO. He returned to Australia in 1989 and joined the University of Queensland in 1991. His current interests are in the molecular virology, diagnosis, vaccine and therapeutic control of dengue and West Nile viruses as well as respiratory syncytial virus and emerging virus infections. He is also investigating the current invasion of the koala genome by a novel retrovirus and its impact on disease in this iconic species.
Paul is a past President of the Australian Society for Microbiology, the Australasian Virology Society and the South East Asian Society for Medical Virology.
Professor Dominic Dwyer trained in microbiology (virology and infectious diseases) at Westmead Hospital’s Institute of Clinical Pathology and Medical Research (ICPMR) in 1986 and became a medical microbiologist in 1997. In 2009, Professor Dwyer was appointed Director and Senior Medical Virologist for ICPMR’s Centre for Infectious Diseases and Microbiology Laboratory Services, part of NSW Health Pathology.
Dominic has extensive experience in pandemic responses, even prior to COVID-19. His work in molecular testing for HIV spans three decades. In 2020 he was selected by the World Health Organization (WHO), to be part of a 15 member international team to work with local health officials in Wuhan to explore the origins of the coronavirus.
He is currently a Clinical Professor at the University of Sydney’s Western Clinical School and recently spent 12 months as a visiting academic in the Service des Maladies Infectieuses et Tropicales at the Hopital Saint-Louis, a public teaching hospital in Paris
If you have any general questions about our products or technology, contact customer support on (07) 3219 0085 or email email@example.com. For all technical support, please email firstname.lastname@example.org.
For all investor-related queries please email email@example.com.